Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27) - A VPAC1 receptor antagonist - Is an inverse agonist on two constitutively active truncated VPAC1 receptors

Peptides

Volumn 25, Issue 11, 2004, Pages 1943-1949

  Vertongen, Pascale ^a   Langlet, Christelle ^a   Langer, Ingrid ^a   Gaspard, Nathalie ^a   Robberecht, Patrick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Chinese hamster ovary cells; CHO; concentration of agonist required for half maximal response; Constitutive activity; EC; EC50; extracellular loops; GRF; Inverse agonism; Truncated recombinant receptors; VPAC1 receptor

Indexed keywords

ADENYLATE CYCLASE; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VPAC 1 [1-398] RECEPTOR; VPAC 1 [1-421] RECEPTOR; VPAC 1 [1-429] RECEPTOR; VPAC 1 [1-433] RECEPTOR; VPAC 1 [1-436] RECEPTOR; VPAC 1 [1-441] RECEPTOR; VPAC 1 [1-444] RECEPTOR; VPAC 1 [1-457] RECEPTOR; VPAC1 RECEPTOR ANTAGONIST; CYCLOPEPTIDE; DIAGNOSTIC AGENT; LIGAND; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO CELL; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; IC 50; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BLOCKING; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; BINDING COMPETITION; CELL CLONE; CHEMISTRY; COMPARATIVE STUDY; CRICETULUS; GENETIC TRANSFECTION; HAMSTER; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PROTEIN CONFORMATION; SYNTHESIS;

CRICETINAE; CRICETULUS GRISEUS;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CLONE CELLS; CRICETINAE; CRICETULUS; HUMANS; INHIBITORY CONCENTRATION 50; IODINE RADIOISOTOPES; LIGANDS; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RECOMBINANT PROTEINS; TRANSFECTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 6344280474     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2004.06.001     Document Type: Article

References (26)

1. Bond R.A., Leff P., Johnson T.D., Milano C.A., Rockman H.A., McMinn T.R., et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature. 374:1995;272-276
2. Carter P.H., Petroni B.D., Gensure R.C., Schipani E., Potts J.T. Jr., Gardella T.J. Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology. 142:2001;1534-1545
3. Couvineau A., Lacapere J.J., Tan Y.V., Rouyer-Fessard C., Nicole P., Laburthe M. Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J Biol Chem. 278:2003;24759-24766
4. De Winter B.Y., Robberecht P., Boeckxstaens G.E., De Man J.G., Moreels T.G., Herman A.G., et al. Role of VIP1/PACAP receptors in postoperative ileus in rats. Br J Pharmacol. 124:1998;1181-1186
5. Dickinson T., Mitchell R., Robberecht P., Fleetwood-Walker S.M. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology. 38:1999;167-180
6. Ganguli S.C., Park C.G., Holtmann M.H., Hadac E.M., Kenakin T.P., Miller L.J. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. J Pharmacol Exp Ther. 286:1998;593-598
7. Gardella T.J., Luck M.D., Jensen G.S., Schipani E., Potts J.T. Jr., Juppner H. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology. 137:1996;3936-3941
8. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 268:1993;19650-19655
9. Gourlet P., Vandermeers A., Vertongen P., Rathe J., De Neef P., Cnudde J., et al. Development of high affinity selective VIP1 receptor agonists. Peptides. 18:1997;1539-1545
10. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 50:1998;265-270
11. Lyu R.M., Germano P.M., Choi J.K., Le S.V., Pisegna J.R. Identification of an essential amino acid motif within the C terminus of the pituitary adenylate cyclase-activating polypeptide type I receptor that is critical for signal transduction but not for receptor internalization. J Biol Chem. 275:2000;36134-36142
12. MacEwan D.J., Milligan G. Up-regulation of a constitutively active form of the beta2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett. 399:1996;108-112
13. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 272:1997;21201-21206
14. Nie J., Lewis D.L. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J Neurosci. 21:2001;8758-8764
15. Nie J., Lewis D.L. The proximal and distal C-terminal tail domains of the CB1 cannabinoid receptor mediate G protein coupling. Neuroscience. 107:2001;161-167
16. Parker E.M., Ross E.M. Truncation of the extended carboxyl-terminal domain increases the expression and regulatory activity of the avian beta-adrenergic-receptor. J Biol Chem. 266:1991;9987-9996
17. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 58:1974;541-548
18. Serre V., Dolci W., Schaerer E., Scrocchi L., Drucker D., Efrat S., et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3'. Endocrinology. 139:1998;4448-4454
19. Simonneaux V., Kienlen-Campard P., Loeffler J.P., Basille M., Gonzalez B.J., Vaudry H., et al. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland. Neuroscience. 85:1998;887-896
20. Usdin T.B., Bonner T.I., Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662-2680
21. Varma D.R., Shen H., Deng X.F., Peri K.G., Chemtob S., Mulay S. Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 127:1999;895-902
22. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 52:2000;269-324
23. Vertongen P., Schiffmann S.N., Gourlet P., Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides. 18:1997;1547-1554
24. Walker J.K., Premont R.T., Barak L.S., Caron M.G., Shetzline M.A. Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor. J Biol Chem. 274:1999;31515-31523
25. Zhu J., Taniguchi T., Takauji R., Suzuki F., Tanaka T., Muramatsu I. Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor. Br J Pharmacol. 131:2000;546-552
26. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed., vol. I, chap. 1, Cold Spring Harbor Laboratory Press.